These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16818282)

  • 1. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.
    Bogen B; Ruffini PA; Corthay A; Fredriksen AB; Frøyland M; Lundin K; Røsjø E; Thompson K; Massaia M
    Haematologica; 2006 Jul; 91(7):941-8. PubMed ID: 16818282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
    Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotypic vaccination as therapy for multiple myeloma.
    Kwak LW; Thielemans K; Massaia M
    Semin Hematol; 1999 Jan; 36(1 Suppl 3):34-7. PubMed ID: 9989488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
    Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of idiotype (Id)-specific T cells in multiple myeloma.
    Bogen B; Schenck K; Munthe LA; Dembic Z
    Acta Oncol; 2000; 39(7):783-8. PubMed ID: 11145433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
    Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
    Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.
    Corthay A; Lundin KU; Munthe LA; Frøyland M; Gedde-Dahl T; Dembic Z; Bogen B
    Cancer Immunol Immunother; 2004 Sep; 53(9):759-69. PubMed ID: 15088126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
    Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
    Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model for immunotherapy of myeloma.
    Bogen B
    Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
    Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of immunotherapy in multiple myeloma.
    Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
    Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S; Haimovich J; Hollander N
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoregulation of murine and human myeloma.
    Hoover RG; Kornbluth J
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):407-24. PubMed ID: 1582982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
    Chiriva-Internati M; Cobos E; Kast WM
    Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.